A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection

Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease

(2018) Kathryn Jones et al.   INFECTION AND IMMUNITY

Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease

(2018) Amadeo B. Biter et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy

(2018) Tiago Senra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

(2016) Christopher A. Seid et al.   Human Vaccines & Immunotherapeutics

The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease

(2015) Lindsey H. Malik et al.   CLINICAL CARDIOLOGY

Detection ofTrypanosoma cruziDNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity

(2015) E. C. Sabino et al.   EUROPEAN JOURNAL OF HEART FAILURE

Old and new challenges in Chagas disease

(2015) Jose A Pérez-Molina et al.   LANCET INFECTIOUS DISEASES

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

(2015) Carlos A. Morillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Usefulness of real time PCR to quantify parasite load in serum samples from chronic Chagas disease patients

(2015) Myllena F Melo et al.   Parasites & Vectors

Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice

(2015) Viridiana Martinez-Campos et al.   VACCINE

A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy

(2015) Isabela Resende Pereira et al.   PLoS Pathogens

Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease

(2014) Isabela Resende Pereira et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Plasma Cytokine Expression Is Associated with Cardiac Morbidity in Chagas Disease

(2014) Giovane Rodrigo Sousa et al.   PLoS One

Real-time PCR strategy for parasite quantification in blood and tissue samples of experimental Trypanosoma cruzi infection

(2012) Sérgio Caldas et al.   ACTA TROPICA

Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

(2012) Eric Dumonteil et al.   Expert Review of Vaccines

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine

(2012) Manmohan Singh et al.   Human Vaccines & Immunotherapeutics

Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment

(2012) José A. Pérez-Molina et al.   Current Infectious Disease Reports

Targeting of Toll-like receptors: a decade of progress in combating infectious diseases

(2011) Mona Hedayat et al.   LANCET INFECTIOUS DISEASES

Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome

(2011) Sabrina Cencig et al.   PLoS Neglected Tropical Diseases

Chagas disease

(2010) Anis Rassi et al.   LANCET

Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: Role of CD4+ and CD8+ T cells

(2010) Alberto Yairh Limon-Flores et al.   VACCINE

The optimization of TaqMan real-time RT-PCR assay for transcriptional profiling of GABA-A receptor subunit plasticity

(2009) Omkaram Gangisetty et al.   JOURNAL OF NEUROSCIENCE METHODS

Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification

(2009) Anis Rassi Jr et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

(2009) Barbara C. Baudner et al.   PHARMACEUTICAL RESEARCH